November 15, 2021
AbbVie said on November 12 that it has filed its IL-23 inhibitor Skyrizi (risankizumab) for an additional indication of Crohn’s disease in Japan. The drug, which was approved in Japan ahead of the rest of the world in March 2019,...read more